US Patent

US10265265 — Topical composition

Formulation · Assigned to Drug Delivery Solutions Ltd · Expires 2027-09-27 · 1y remaining

Vulnerability score 55/100 Moderate — design-around opportunities exist

What this patent protects

This patent protects a topical composition containing a polyaphron dispersion, vitamin D or a vitamin D analog, and a corticosteroid.

USPTO Abstract

A composition suitable for topical application comprising a continuous phase and at least one discontinuous phase, said composition comprising at least one polyaphron dispersion, at least one vitamin D or vitamin D analog and at least one corticosteroid.

Drugs covered by this patent

Diprolene (BETAMETHASONE DIPROPIONATE) · Merck & Co.

Patent Metadata

Patent number: US10265265
Jurisdiction: US
Classification: Formulation
Expires: 2027-09-27
Drug substance claim: No
Drug product claim: Yes
Assignee: Drug Delivery Solutions Ltd
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.